News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article first appeared on GuruFocus. Adjusted Net Revenue: Grew 9.4% year over year, reflecting tariff adjustments and customer expansion. Adjusted EBITDA: Totaled BRL3.5 billion, down 2.3% year over year, with an EBITDA margin of 58.3%. Adjusted Net Income: Reached BRL1.2 billion, with the …
This article first appeared on GuruFocus. Consolidated EBITDA: Increased 5% quarter-on-quarter and year-on-year, driven by better operational performance across all segments. Free Cash Flow: Positive at BRL808 million, a significant reversal after negative quarters, supported by working capital release and fundraising. Leverage: Net debt/EBITDA …
This article first appeared on GuruFocus. Adjusted Net Revenue: Grew 9.4% year over year, reflecting tariff adjustments and customer expansion. Adjusted EBITDA: Totaled BRL3.5 billion, down 2.3% year over year, with an EBITDA margin of 58.3%. Adjusted Net Income: Reached BRL1.2 billion, with the …
Sharemaestro market context Trend signal ended 52 weeks +27.9% · Next-week setup positive 59.5%This article first appeared on GuruFocus. Consolidated EBITDA: Increased 5% quarter-on-quarter and year-on-year, driven by better operational performance across all segments. Free Cash Flow: Positive at BRL808 million, a significant reversal after negative quarters, supported by working capital release and fundraising. Leverage: Net debt/EBITDA …
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 9.99% of the class. This stake includes common shares and pre-funded warrants, with the exercise of …
Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 4.30% in Inhibikase Therapeutics (IKT), totaling 5,810,487 shares as of June 30, 2026. This stake includes 3,108,624 shares acquirable through convertible securities within sixty days. The …
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have disclosed a beneficial ownership of 6.9% in Inhibikase Therapeutics, Inc. (IKT) through warrants. This stake, totaling 10,320,875 shares, is primarily held by the Master Fund through various pre-funded and common warrants, …
Schonfeld Strategic Advisors LLC has disclosed a 5.33% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) through a Schedule 13G filing. This amounts to 781,678 shares of common stock, representing 5.33% of the 14,671,186 shares outstanding as of May 8, 2026. Schonfeld maintains sole …
Key Points Interested in Comp En De Mn Cemig ADS? Here are five stocks we like better. Cemig reported solid second-quarter results: recurring EBITDA rose 9.3% year over year to BRL 2.5 billion, while recurring net income increased 15.6%. The company is maintaining its …
Inhibrx Biosciences (NASDAQ:INBX) experienced a share price drop after missing earnings estimates, opening at $91.80, down from its previous close of $97.01. The company reported an EPS of $(2.34) against an estimated $(2.28). Analyst ratings for INBX are mixed, with an average "Hold" rating …
National Health Investors, Inc. (NYSE:NHI) has received a "Moderate Buy" consensus recommendation from eight brokerages, with an average 12-month price target of $83.86, significantly higher than its current share price of $71.23. The company also reported strong quarterly earnings of $1.19 EPS on $121.32 …
Inhibrx Biosciences (NASDAQ:INBX) has received a consensus "Hold" recommendation from brokerages, with an average 12-month price target of $150.00. The company recently reported a quarterly EPS of -$2.34, missing analyst estimates, and institutional investors now own 82.46% of the stock. BlackRock Inc. notably acquired …
* Companhia Energética de Minas Gerais - CEMIG press release [https://ri.cemig.com.br/docs/Press-release-Cemig-2026-06-30-7pTb6qGD.pdf] (CIG [https://seekingalpha.com/symbol/CIG]): Q2 Revenue of R$11.16B (+3.4% Y/Y). * Consolidated EBITDA grew 8.8% YoY in 2Q26 and totaled R$2.24 billion, while Adjusted EBITDA was R$2.47 billion, up 9.3% from 2Q25. * Cemig reported …
Key Points Interested in Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp? Here are five stocks we like better. Revenue grew but profitability declined: Adjusted revenue rose 9.4% year over year, including EMAE, supported by tariff increases and customer additions. Adjusted …
Companhia Siderúrgica Nacional (CSN) reported stronger-than-expected Q2 2026 results, exceeding Wall Street forecasts for both earnings and revenue, driven by improved performance across its diversified segments including steel, mining, cement, logistics, and energy. The company also achieved positive free cash flow and a modest …
Companhia Siderúrgica Nacional (SID) released its Q2 2026 earnings call presentation on August 13, 2026. The company reported an EPS of -$0.12, missing estimates by $0.09, and revenue of $2.18 billion, which beat estimates by $29.47 million and represented a 12.86% year-over-year increase. The …
Inhibrx Biosciences (NASDAQ:INBX) reported a quarterly loss of $2.34 per share, missing analysts' consensus estimates by $0.06. Following the announcement, the stock fell 1.4% to $97.01. Despite mixed analyst sentiment resulting in a "Hold" rating, institutional investors hold a significant 82.46% of the company's …
Companhia de Saneamento Básico do Estado de São Paulo – Sabesp (SBS) stock has fallen over 7% due to privatization uncertainty, breaking a multi-week uptrend. While SBS is a large, utility-style company with steady revenues and a stable profit margin, its recent price action …
This article reports on the filing of a Form 8K by Inhibrx Biosciences Inc. for August 13. The brief notice highlights the company's regulatory submission without providing further details on its content. It includes the stock symbol INBX, which saw a slight decrease.
Inhibrx Biosciences (INBX) reported a net loss of $70.1 million for the first half of 2026, with no revenue, while holding $133.3 million in cash and equivalents. Despite the losses, the company advanced its clinical pipeline, with ozekibart achieving a statistically significant progression-free survival …
Inhibrx reported a net loss of $36.7 million in Q2 2026, with R&D expenses at $23.9 million and G&A at $8.3 million. The company secured an amended loan with Oxford Finance for up to $325.0 million, with $100.0 million already funded. The FDA accepted …
The 12-month average price target for Companhia Siderurgica Nacional S.A. (CSNA3) stock has been raised from $1.53 to $1.54 by 11 analysts, with a potential upside of 78% based on the August 12 closing price. Despite the increased price target, the consensus rating for …
Sabesp (Companhia de Saneamento Basico do Estado de Sao Paulo) reported a second-quarter profit of $289.7 million, with earnings of 7 cents per share when adjusted for non-recurring gains. The waste management company achieved revenue of $1.3 billion during the same period. This data …
Search by ticker symbol or company name and select a result to open its chart.